The QualityStocks Daily Tuesday, July 23rd, 2024

Today's Top 3 Investment Newsletters

QualityStocks(SLRX) $2.6100 +69.48%

SmallCapRelations(ICLK) $2.1400 +28.14%

MissionIR(SBEV) $0.3590 +12.29%

The QualityStocks Daily Stock List

Salarius Pharmaceuticals (SLRX)

QualityStocks, StockMarketWatch, Stocks That Move, MarketBeat, StocksEarning, Premium Stock Alerts, Money Wealth Matters and 360 Wall Street reported earlier on Salarius Pharmaceuticals (SLRX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Salarius Pharmaceuticals Inc. (NASDAQ: SLRX) (FRA: FP11) is a clinical stage biotechnology firm that is engaged in the development of cancer treatments that are epigenetic-based. Epigenetic refers to the regulatory system that influences gene expression.

Salarius Pharmaceuticals Inc. operates in the biotechnology industry, under the healthcare sector and is based in Houston, Texas. The firm, which was known as Flex Pharma Inc. before changing its name has been granted Product Development Award funding that totals $18.7 million by the Cancer Prevention and Research Institute of Texas in addition to other funding by the National Pediatric Cancer Foundation for the advancement of the Ewing sarcoma clinical program. Salarius Pharmaceuticals Inc. serves consumers and patients in the U.S. and was established in 2014.

Salarius Pharmaceuticals is party to strategic partnerships with the Cancer Prevention and Research Institute of Texas for various activities that entail product development; HLB Life Sciences for the development, manufacture, production and sale of the SP-2577 candidate in South Korea and the University of Utah Research Foundation for the license to patent rights that protect SP-2577 and associated compounds.

Salarius Pharmaceuticals Inc.’s product pipeline includes its lead candidate; seclidemstat, which is undergoing a phase 1/2 clinical trial for relapsed or refractory Ewing sarcoma. The candidate, which is also known as SP-2577, is also undergoing phase 1/2 clinical trials that evaluate its efficacy in treating advanced solid tumors, including ovarian, breast and prostate cancers.

As of 2020, the firm’s SP-2577 candidate had been awarded Rare Pediatric Disease Designation, Orphan Drug Designation and Fast Track Designation by the FDA. Seclidemstat employs a new approach to treat/improve Ewing sarcoma, which will not only benefit patients by addressing a previously unmet medical need but also extend the firm’s reach in the market, which will be good for its growth and investment opportunities.

Salarius Pharmaceuticals (SLRX), closed Tuesday's trading session at $2.61, up 69.4805%, on 60,036,552 volume. The average volume for the last 3 months is 2.774M and the stock's 52-week low/high is $1.35/$8.48.

Adial Pharmaceuticals (ADIL)

MarketClub Analysis, QualityStocks, StockMarketWatch, BUYINS.NET, TopPennyStockMovers, MarketBeat, InvestorsUnderground, PennyStockProphet, PennyStockScholar, 360wallstreet, Schaeffer's, TradersPro, Small Cap Firm, StreetInsider, The Online Investor, Timothy Sykes and PoliticsAndMyPortfolio reported earlier on Adial Pharmaceuticals (ADIL), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Adial Pharmaceuticals Inc. (NASDAQ: ADIL) is a clinical-stage biopharmaceutical firm that is engaged in developing treatments for preventing or treating addiction and associated disorders.

The firm has its headquarters in Charlottesville, Virginia and was incorporated in November 2010 by Bankole A. Johnson. It operates as part of the pharmaceutical manufacturing industry, under the healthcare sector, in the biotech and pharma sub-industry and serves consumers in Virginia.

The enterprise’s pipeline is made of a selective serotonin-3 antagonist dubbed AD04, which is indicated for treating alcohol use disorder. The active ingredient in the formulation, i.e. ondansetron, is the serotonin-3 antagonist. The formulation has also been indicated for the treatment of other addictive disorders including smoking, obesity and opioid use disorder, among other drug addictions. The candidate recently concluded its phase 2b study which tested its effectiveness in treating alcohol use disorders, and it demonstrated promising results in decreasing the quantity and frequency of heavy drinking and drinking in general, with no noticeable safety concerns. The enterprise also develops AD01, which is indicated for treating addictive behaviors, and recently concluded phase 1 trials. In addition to this, the enterprise is also involved in the development of drug candidates for non-opioid pain alleviation and other disorders and ailments.

The firm is planning to venture into the genetic testing market after receiving a patent for its AD04 candidate, bringing the firm one step closer to helping identify patients that could benefit from their formulation. This move will also allow the firm to commercialize a companion diagnostic test to AD04 in the future, which will help extend its consumer reach and in turn, bring in even more investors.

Adial Pharmaceuticals (ADIL), closed Tuesday's trading session at $1.31, up 23.5849%, on 160,038,273 volume. The average volume for the last 3 months is 97,908 and the stock's 52-week low/high is $0.765/$8.875.

Hoth Therapeutics (HOTH)

QualityStocks, StreetInsider, StockMarketWatch, RedChip, PennyStockProphet, Broad Street, MarketClub Analysis, OTCtipReporter, Penny Pick Finders, PennyStockLocks, StockRockandRoll, Penny Stock 101, OTCBB Journal, BUYINS.NET, HotOTC, StockOnion, MarketBeat, Schaeffer's, INO Market Report, Profitable Trader Authority, Buzz Stocks, PennyStockScholar, StockHideout, Planet Penny Stocks, 247 Market News and TradersPro reported earlier on Hoth Therapeutics (HOTH), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Hoth Therapeutics Inc. (NASDAQ: HOTH) is a biopharmaceutical firm that is focused on the development of therapies for atopic dermatitis and other ailments such as psoriasis, acne, asthma and chronic wounds.

The firm, which serves consumers in the United States and is based in New York, was founded in May 2017 by James Ahern, Matthew D. Eitner and Robbie Knie.

Hoth Therapeutics is engaged in the development of eczema therapies, having developed its therapeutic platform called BioLexa Platform, which is a patented and drug compound platform for the treatment of eczema. This product is designed to prevent any flare-ups that can trigger eczema symptoms even before they occur. The firm also explores the use of its platform in the aesthetic dermatology field to help reduce and treat post-procedure infections, improve clinical outcomes for individuals undergoing procedures and speed up the healing process.

The company recently entered into 2 separate agreements to develop 2 vaccine prospects for treating and preventing the coronavirus. This is in addition to successfully completing a pre-IND meeting with the FDA for its HT-001 product, which is indicated for the treatment of skin disorders and rashes in cancer patients.

Cancer patients who suffer from various dermatological diseases during epidermal growth factor receptor inhibitor treatment may soon have an answer to their problems, in form of Hoth Therapeutics’ HT-001. With positive feedback from the FDA, the company is not far from approval.

Hoth Therapeutics (HOTH), closed Tuesday's trading session at $0.971951, up 15.7774%, on 439,278 volume. The average volume for the last 3 months is 228,413 and the stock's 52-week low/high is $0.72/$3.37.

UTime Ltd (WTO)

QualityStocks and MarketClub Analysis reported earlier on UTime Ltd (WTO), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

UTime Ltd (NASDAQ: WTO) is focused on designing, developing, manufacturing and selling communication equipment like mobile phones, accessories and related consumer electronics.

The firm has its headquarters in Shenzhen, the People’s Republic of China and was incorporated in June 2008 by Bo Tang, Junlin Zhou and Minfei Bao. The firm serves consumers around the globe, with a primary focus on Southeast Asia, South Asia, South America, the United States and Africa.

The company’s operations are based in China, with most of its products being sold globally. It operates through a pair of in-house brands, i.e. “Do”, a low-to-mid-end brand which is positioned to target the majority of price-sensitive consumers and grassroots consumers in emerging markets; and “UTime”, a middle-to-high-end label which targets middle class consumers from various emerging markets.

The enterprise’s consumer electronics include batteries, Bluetooth speakers, power banks, chargers and cell phone shells, molds and parts. It also distributes face masks. This is in addition to providing electronics manufacturing services, which include original design manufacturer and original equipment manufacturer services for well-known brands like Quality One Wireless LLC, which is based in Florida; Haier Electronics Group Co. Ltd, which is a Haier Group Corp subsidiary; and TCL Communication Technology Holdings Ltd, which is a TCL Corp subsidiary.

The company is planning to build manufacturing facilities for the production of smart telecom devices in the city of Nanning, China. This move will allow the company to strengthen its research, development and production capabilities while developing its new generation of smart telecom devices and improving its ecosystem in the industry value chain.

UTime Ltd (WTO), closed Tuesday's trading session at $0.95, up 14.1141%, on 223,737 volume. The average volume for the last 3 months is 212,031 and the stock's 52-week low/high is $0.1272/$1.14.

Eledon Pharmaceuticals (ELDN)

QualityStocks and MarketBeat reported earlier on Eledon Pharmaceuticals (ELDN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Eledon Pharmaceuticals Inc. (NASDAQ: ELDN) (FRA: 2TK) is a clinical stage biopharmaceutical firm that is engaged in the development of medications for individuals living with amyotrophic lateral sclerosis and autoimmune ailments.

The firm has its headquarters in Irvine, California and was incorporated in 2004, on March 26th. Prior to its name change in January 2021, the firm was known as Novus Therapeutics Inc. The firm serves consumers in the United States.

The company uses its expertise to target the CD40L pathway to develop new treatments for individuals with neurodegenerative and autoimmune ailments, as well as for individuals undergoing organ or cellular transplantation. The CD40L/CD40 pathway is known for its important role in immune regulation, which makes it a candidate for therapeutic intervention in neuro-inflammation, autoimmune ailments and transplant tolerance.

The enterprise’s product pipeline comprises of a humanized monoclonal antibody dubbed AT-1501, which targets CD40 ligand that’s a molecule expressed on the surface of T cells in the human immune system. The formulation is built upon a historical understanding of the CD40/CD40L pathway. It is currently in phase 2 clinical trials evaluating its effectiveness in treating amyotrophic lateral sclerosis. In addition to this, the formulation is also undergoing phase 2 clinical trials in islet cell transplantation, for treating type 1 diabetes.

The company recently entered into a collaborative research agreement with CareDx Inc. which will entail evaluating the effectiveness of the company’s AT-1501 formulation using CareDx’s technology. This agreement moves the company one step closer to getting its AT-1501 formulation to approval and will also bring in more opportunities for the company, which will be good for its growth.

Eledon Pharmaceuticals (ELDN), closed Tuesday's trading session at $3.13, up 13.4058%, on 843,319 volume. The average volume for the last 3 months is 72,813 and the stock's 52-week low/high is $1.07/$3.349.

Forward Industries (FORD)

StockOodles, TradersPro, Wall Street Resources, SmarTrend Newsletters, MarketBeat, QualityStocks, The Street, OTCPicks, BUYINS.NET, Jason Bond, InvestorsUnderground, Marketbeat.com, PennyToBuck, DrStockPick, Jet-Life Penny Stocks, InvestorPlace, Equity Observer, CRWEWallStreet, CRWEPicks, CRWEFinance, Hot Stock Profits, MarketClub Analysis, BestOtc, PennyOmega, Zacks, Shiznit Stocks, Stock Beast, Stock Commander, StockHotTips, Street Insider, StreetInsider, TopPennyStockMovers, Value Penny Stocks and Penny Stock General reported earlier on Forward Industries (FORD), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Forward Industries Inc. (NASDAQ: FORD) is a single source solution provider that is focused on designing, marketing and distributing smart products, IoT technology solutions and soft goods.

The firm has its headquarters in Hauppauge, New York and was incorporated in 1961. It serves consumers around the globe and sells its products to original equipment manufacturers in Africa, the Middle East, Europe, the Americas and the Asia Pacific.

The company has grown its ability to design and develop solutions for its multi-national client base, via the acquisition of Intelligent Product Solutions Inc. It uses this subsidiary to offer software and hardware product design and engineering services. The company operates through the design and distribution segments.

The enterprise, which is also focused on designing and distributing carry and protective solutions mainly for hand held electronic devices, is also engaged in the provision of carrying cases as well as other accessories for diagnostic kits and medical monitoring kits. It also offers non-electronic and other portable electronic products which include firearms, tablets, GPS location devices, smartphones, barcode scanners, recreational products and sporting products. The enterprise’s services include optical engineering, industrial design, software engineering, mechanical engineering, electrical engineering, marketing and Internet of Things system architecture.

The company recently announced its latest financial results, which show an increase in revenues, with its CEO noting that the company is focused on expanding and diversifying its products. This move will help bring in additional revenue into the firm, which may encourage more investments into the company.

Forward Industries (FORD), closed Tuesday's trading session at $4.36, up 11.509%, on 69,998 volume. The average volume for the last 3 months is 67,422 and the stock's 52-week low/high is $3.55/$9.40.

Accelerate Diagnostics (AXDX)

The Street, MarketBeat, QualityStocks, InvestorPlace, Marketbeat.com, Money Morning, StreetInsider, CustomerService, Schaeffer's, TradersPro, Barchart, INO.com Market Report, Kiplinger Today, Agora Financial, Street Insider, StreetAuthority Daily, Money Wealth Matters, Trader Prep, Schaeffer’s, Daily Trade Alert, Daily Market Beat, Shah's Insights & Indictments, StockMarketWatch and The Online Investor reported earlier on Accelerate Diagnostics (AXDX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Accelerate Diagnostics Inc. (NASDAQ: AXDX) (FRA: 1AB) (BMV: AXDX) is an in vitro diagnostics firm that is engaged in the provision of solutions for diagnosing severe bacterial infections.

The firm has its headquarters in Tucson, Arizona and was incorporated in 1982, on May 26th. Prior to its name change in December 2012, the firm was known as Accelr8 Technology Corp. The firm serves consumers in the Middle East, Europe and the United States, as well as the worldwide healthcare sector.

The company’s platform, the Accelerate ID/AST system, is used to determine if live fungal or bacterial cells observed in a sample are defenseless against a specific antibiotic. The system can also analyze positive blood culture samples in about 5 hours, which is faster, in comparison with conventional testing methods.

The enterprise offers a test kit for its system known as the Accelerate PhenoTest, which identifies and tests for antibiotic susceptibility in patients who may have fungemia or bacteremia, which are both life-threatening conditions with high mortality and morbidity risk. In addition to this, it provides an in vitro diagnostic platform known as the Accelerate Pheno system, which identifies and tests for antibiotic susceptibility of pathogens linked to severe healthcare-associated infections including gram-negative and gram-positive organisms.

The firm’s new IVD Accelerate PhenoTest BC kit configuration was recently CE marked and will soon be available in Europe. This move not only offers options that accommodate the different lab and clinical settings in Europe but will also extend the firm’s consumer reach, which may in turn boost its growth.

Accelerate Diagnostics (AXDX), closed Tuesday's trading session at $1.29, up 11.2069%, on 133,999 volume. The average volume for the last 3 months is 383,809 and the stock's 52-week low/high is $0.73/$7.58.

Ryde Group (RYDE)

We reported earlier on Ryde Group (RYDE), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Ryde Group Ltd (NYSE American: RYDE) (FRA: D0S) is an investment holding firm engaged in the provision of mobility and quick commerce solutions in Singapore.

The firm has its headquarters in Singapore and was incorporated in 2014. It operates as part of the software-application industry, under the technology sector. The firm primarily serves consumers in Singapore.

The company’s mission is to leverage technology to transform the movement of people and goods.

The enterprise, through its subsidiaries and technology-driven platform, provides mobility and quick commerce solutions to its consumers. Its core business is divided into 2 categories; Mobility and Quick Commerce. Its Mobility business segment offers flexible and scheduled carpooling and ride-hailing services, matching riders with its network of driver partners. Its ride-hailing services allow riders to determine the number of seats they require for the trip, and offers real-time, on-demand bookings as well as advance bookings and multi-stop options. Its different service offerings include RydeTAXI, RydeX, RydePET, RydeXL, RydeFLASH, RydeHIRE, and RydeLUXE services. On the other hand, its Quick Commerce business segment is a package delivery booking service, which enables driver partners to accept bookings for package delivery services through its driver partner app.

The firm recently entered into a partnership with Mobile-health Network Solutions, which will further collaboration in the quick commerce and telehealth space. This move will improve the well-being of Ryde’s driver-partners while offering them access to affordable healthcare services. In addition to this, it will open the firm up to new growth and investment opportunities that may generate additional value for its shareholders.

Ryde Group (RYDE), closed Tuesday's trading session at $6.68, off by 1.037%, on 23,432 volume. The average volume for the last 3 months is 9.283M and the stock's 52-week low/high is $2.0202/$11.00.

Canopy Growth Corp. (CGC)

InvestorPlace, Schaeffer's, The Street, MarketClub Analysis, Trades Of The Day, StocksEarning, StockEarnings, MarketBeat, Daily Trade Alert, Kiplinger Today, QualityStocks, The Online Investor, Wealth Insider Alert, Streetwise Reports, StreetInsider, CFN Media Group, Market Intelligence Center Alert, Investopedia, Zacks, StreetAuthority Daily, Stock Up Featured, The Wealth Report, Daily Profit, Top Pros' Top Picks, SmallCapVoice, StockMarketWatch, Lebed.biz, Wall Street Grand, SeriousTraders, Early Bird, INO Market Report, Profit Trends, Money Morning, BUYINS.NET, Louis Navellier, Cannabis Financial Network News, CNBC Breaking News, Investors Underground, Inside Trading, Jim Cramer, Outsider Club, StocksToBuyNow, Trading For Keeps, MarketClub, Technology Profits Daily, AllPennyStocks, Beat The Street, Wealth Daily, Cabot Wealth, VectorVest, CannabisNewsWire, Trading Concepts, TradersPro, Timothy Sykes, Profit Confidential, TheTradingReport, Insider Wealth Advice, Investment U, InvestmentHouse, Stock Gumshoe, Investors Alley, Rick Saddler, Raging Bull All Access, 24/7 Trader, Money and Markets and Tim Bohen reported earlier on Canopy Growth Corp. (CGC), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Hemp has various applications, with its stalk being made of fibers that are flexible and soft. Hurds, the plant’s woody inner core, are hard and rigid. Americhanvre, a company offering hemp-building solutions, recently passed a fire-resistance test for its product, Ereasy.

The Ereasy system is a spray-on application kit that delivers hempcrete, which is a construction material that has been used in construction for centuries. For instance, hempcrete plaster was applied more than 1,000 years ago on the walls of Ellora Caves in India. The manmade caves are a World Heritage site and were cut into rock then plastered from the inside. Another example is a bridge abutment in France that may have been built as early as the sixth century AD.

Hempcrete, which normally comprises of chipped/shredded hemp hurd, water and lime, may also include cement, clay and other additives. The benefits of this durable and light building material include its fire resistance, nontoxic byproducts, high thermal mass, resistance to mold and pests, sound dampening, carbon sequestration capabilities and breathability.

The substance’s carbon sequestration attributes are especially interesting because hemp not only stores carbon as it grows but hempcrete continues to absorb carbon even as a product. It should be noted, however, that hempcrete is not as strong as traditional concrete.

The Ereasy spray-on product was developed in France about 10 years ago, with Americhanvre Cast Hemp becoming the product’s distributor in the North American region a few years ago. Americhanvre announced recently that this hempcrete product had received a one-hour rating on fire resistance under ASTM E-119. This is the standard used to measure the response of assemblies, products or materials to flame and heat under controlled conditions.

Americhanvre revealed that this was the first time a full-scale test had been conducted on a section of hempcrete wall. In its statement, the company explained that the panel’s exterior face, which had sensors, wasn’t damaged even after firing at 1,700o F for 60 minutes with a hose stream test conducted soon after.

It is noted in the report that the panel’s temperature never rose higher than the ambient temperature. Americhanvre added that the official rating supported Ereasy hempcrete’s fire resistance attributes in the United States. This new rating will allow the company to access larger-scale commercial projects for this hempcrete system in America.

In 2023, the company’s ASTM C-518 thermal resistance product was confirmed to have an R value of R2.2 per inch, based on European data. In addition to insulation, hemp is also utilized in other building products, such as particle board.

In the future, the use of hurd in the manufacture of various construction materials could provide an economically viable way to use some of the biomass waste after cannabis companies such as Canopy Growth Corp. (NASDAQ: CGC) (TSX: WEED) have extracted the parts of the plant that they use in making their primary products.

Canopy Growth Corp. (CGC), closed Tuesday's trading session at $8.2, off by 1.7964%, on 7,916,610 volume. The average volume for the last 3 months is 403,759 and the stock's 52-week low/high is $2.755/$19.20.

Compass Pathways PLC (CMPS)

InvestorBrandNetwork, QualityStocks, InvestorPlace, MarketBeat, PsychedelicNewsWire, Daily Trade Alert, Top Pros' Top Picks, StreetInsider, Schaeffer's, Prism MarketView, Trades Of The Day and The Street reported earlier on Compass Pathways PLC (CMPS), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

New research has determined that psilocybin may impact the brain. Psilocybin is the primary psychoactive compound found in hallucinogenic mushrooms. When ingested, it distorts an individual’s perception of time, among other changes.

Researchers have observed that in animals, psilocybin causes neuroplasticity in the hippocampus and cortex. The new study was carried out by investigators at the Washington University School of Medicine in St. Louis. For their study, the researchers used functional MRI scans to observe brain activity in seven healthy individuals prior to, during and after they consumed methylphenidate or psilocybin.

During the trial, 40 mg of methylphenidate and 25 mg of psilocybin was administered to the healthy participants. Their objective was to establish a connection between subjective experiences and changes in brain networks.

Each of the participants was required to rate their feelings of awe, connectedness and transcendence of space and time via questionnaire while under the influence of psilocybin. To do this, the researchers used the Mystical Experience Questionnaire, which measures the quality and intensity of mystical experience with a maximum score of 150.

They observed that the changes in an individual’s functional networks correlated with the intensity of their subjective experience. Dr. Ginger E. Nicol, the cosenior author of the study, explained that this allowed the researchers to collect accurate data on psilocybin’s effects in each participant. Nicol added that utilizing this approach in clinical trials could help identify what determines individuals who benefit or don’t benefit from these drugs, as well as how to make better use of the drugs.

In their report, the researchers explained that psilocybin temporarily interrupts the default mode network, which is involved in introspective thinking. This disruption induces the psychedelic experience and may explain the psychedelic’s potential to treat mental-health conditions such as post-traumatic stress disorder and depression.

Dr. Joshua S. Siegel, the first author of the study, stated that while much is known about the psychological and cellular/molecular effects of psilocybin, less is known about what happens inside the brain. The researchers observed that after psilocybin’s serious effects had worn off, minute differences observed in scans taken prior to the drug’s administration persisted.

In their report, the scientists warn against self-medicating with psilocybin because the drug isn’t approved for use by the U.S. Food and Drug Administration. They also highlight the importance of conducting human clinical trials to better understand the basis of the behavioral effects of psychedelics.

The researchers reported their findings in the “Nature” journal.

With other ongoing studies on psilocybin by enterprises such as Compass Pathways PLC (NASDAQ: CMPS), the mysteries of this psychedelic compound are likely to be largely unlocked over the coming years.

Compass Pathways PLC (CMPS), closed Tuesday's trading session at $7.27, off by 2.1534%, on 654,842 volume. The average volume for the last 3 months is 509,852 and the stock's 52-week low/high is $5.01/$12.75.

Trulieve Cannabis Corp. (TCNNF)

QualityStocks, InvestorPlace, MarketBeat, Wealth Insider Alert, Daily Trade Alert, Cabot Wealth, Top Pros' Top Picks, The Street, Trades Of The Day, Profit Trends, CannabisNewsWire, TradersPro, The Online Investor, StreetInsider and Prism MarketView reported earlier on Trulieve Cannabis Corp. (TCNNF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Curaleaf Holdings had decided to step away from hemp. The New York-based cannabis multistate operator initially ran a hemp farm in Lexington, Kentucky, for its CBD product line starting in 2018. According to its annual filings, Curaleaf terminated its lease, stopped all hemp-related manufacturing and wholesale operations in Kentucky by the end of September last year and listed its assets for sale.

However, Curaleaf recently reentered the hemp business, following a larger cannabis industry trend for licensed businesses. The company introduced a new range of THC-derived hemp products on June 24, 2024, under The Hemp Co. brand.

The hemp-based, shelf-stable intoxication products, including drinks, candy and other items bearing the Curaleaf brand, are legal across 25 state lines and can be purchased online and through well-known retailers such as DoorDash.

Matt Darin, Curaleaf CEO, stated that there wasn’t a single “eureka moment” that influenced the company’s decision. According to him, spending time with legislators in Washington, where Farm Bill 2018 unintentionally legalized a national trade in hemp-derived THC, highlighted a key point: hemp is legal at the federal level, while cannabis is not.

Despite Curaleaf’s strong advocacy for marijuana reform, this legal distinction significantly influenced the company’s strategy. The shift mirrors a broader industry trend of large MSOs embracing hemp.

Curaleaf, as with a lot of big MSOs, is a member of the U.S. Cannabis Council, a D.C.-based lobbying group representing licensed cannabis businesses. The group wrote to federal lawmakers in April urging them to eliminate the loophole in Farm Bill 2018 that allowed hemp-derived cannabinoids to be sold legally across the country. The regulatory change hasn’t happened yet, though.

In response, instead of pushing for stricter regulations on intoxicating hemp products, which face less taxation and regulatory burden than state-legal cannabis, MSOs are entering the hemp market.

Alongside Curaleaf, Green Thumb Industries, based in Chicago, has granted hemp-derived company Urb a license to use its Incredibles edibles trademark.

Whether more companies will follow this path or focus on opening new recreational markets remains to be seen. For instance, Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) has invested more than $40 million in a recreational cannabis legalization ballot measure in Florida.

Meanwhile, Capitol Hill’s lax attitude toward hemp may be about to change. Representative Mary Miller (R) proposed an amendment in the House version of the Farm Bill in late May that would outlaw THC-containing edible hemp products.

While the GOP-dominated House Committee on Agriculture has progressed with a farm bill draft that includes this prohibition, neither the Democratic-controlled Senate nor the entire House of Representatives have seriously addressed it as of yet. It’s also unclear if Congress will approve a farm bill this year.

For now, the status quo permits the sale of THC products derived from hemp online and across state borders, with some state-specific restrictions. This ongoing opportunity for brand expansion remains highly attractive.

Trulieve Cannabis Corp. (TCNNF), closed Tuesday's trading session at $10.97, up 2.0465%, on 463,316 volume. The average volume for the last 3 months is 11.953M and the stock's 52-week low/high is $3.42/$14.50.

PayPal Holdings (PYPL)

InvestorPlace, Kiplinger Today, The Street, MarketClub Analysis, Schaeffer's, MarketBeat, The Online Investor, Trades Of The Day, Daily Trade Alert, StocksEarning, Zacks, StreetInsider, Investopedia, Market Intelligence Center Alert, StockEarnings, The Wealth Report, Early Bird, Louis Navellier, GorillaTrades, Wealth Insider Alert, Top Pros' Top Picks, Barchart, StreetAuthority Daily, Marketbeat.com, Daily Wealth, StrategicTechInvestor, MarketWatch, Trading Tips, Cabot Wealth, Trading Concepts, INO Market Report, Money Wealth Matters, Uncommon Wisdom, CNBC Breaking News, TopStockAnalysts, Daily Profit, Profit Confidential, Market Intelligence Center, Jon Markman’s Pivotal Point, Money and Markets, Investors Alley, Money Morning, FreeRealTime, CustomerService, ProfitableTrading, Wyatt Investment Research, TipRanks, SmallCapVoice, Smartmoneytrading, StockMarketWatch, The Street Report, Investiv, AllPennyStocks, TradersPro, InsiderTrades, Investing Daily, Investing Signal, Investment House, TheOptionSpecialist, The Stock Dork, Stock Up Featured, Investing Lab, Trader Prep, Equities.com, Energy and Capital, Earnings360, Traders For Cash Flow, Eagle Financial Publications, DividendStocks, Penny Stock, Wallstreet Journal, INO Traders Blog, Daily Dividends, Weekly Wizards, WStreet Market Commentary, Chaikin PowerFeed, Schaeffer’s, BUYINS.NET, wyatt research newsletter, Average Joe Options, Rick Saddler, Wall Street Daily, MarketClub, Market FN, The Best Newsletters, Kiplinger’s Weekly Update, The Disciplined Trader, The Night Owl, Jim Cramer, Street Insider, MarketArmor.com, Total Wealth, InvestmentHouse, Short Term Wealth, QualityStocks, Stock Market Watch, Milestone Capital Growth Portfolio, Investing Futures, 24/7 Trader, SmallCapNetwork, Insider Wealth Alert, INO.com Market Report, The 10-Minute Millionaire and Investor Guide reported earlier on PayPal Holdings (PYPL), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

PayPal Holdings (NASDAQ: PYPL) is gearing up for its upcoming earnings report, with Wall Street setting the stage for an interesting outcome. The company, a giant in the digital payments space, competes with other financial technology firms to facilitate online money transfers and payment processing for consumers and businesses worldwide. As the earnings date approaches, expectations are mixed, with analysts predicting a dip in earnings per share (“EPS”) year-over-year but projecting an uptick in revenues for the quarter ending June 2024.

The consensus among analysts suggests an EPS of $0.96, which would represent a 17.2% decrease from the previous year. However, revenues are expected to climb by 6.8% to reach $7.78 billion. This mixed forecast reflects the complex dynamics at play in the digital payments sector, where PayPal continues to expand its market presence. The company’s valuation metrics, such as the price-to-earnings (P/E) ratio of approximately 14.78 and the price-to-sales (P/S) ratio of about 2.07, underscore its moderate valuation in the competitive landscape.

Recent optimism is evident from the upward revision of the consensus EPS estimate by 0.38% over the last 30 days, hinting at analysts’ growing confidence in PayPal’s performance. This adjustment may stem from the latest business insights or operational improvements within the company. Furthermore, PayPal’s Earnings ESP (Expected Surprise Prediction) of +2.96%, coupled with a Zacks Rank of #1 (Strong Buy), points towards a strong possibility of an earnings beat. This potential outcome is supported by PayPal’s track record of surpassing consensus EPS estimates in three of the last four quarters.

Financial ratios such as the enterprise value to sales (EV/Sales) and the enterprise value to operating cash flow (EV/OCF) provide additional context to PayPal’s valuation. With an EV/Sales ratio of around 2.07 and an EV/OCF ratio of approximately 11.28, these figures suggest that the market values PayPal’s sales and operating cash flow at a healthy level, reflecting its solid business model and operational efficiency. The earnings yield of about 6.77% further offers investors insight into the potential return on investment from PayPal’s earnings.

As investors and analysts await the earnings call, they will be looking for insights into PayPal’s business conditions, future prospects, and how the company plans to navigate the challenges and opportunities ahead. The combination of anticipated revenue growth, valuation metrics, and the potential for an earnings beat makes the upcoming earnings report a pivotal moment for PayPal.

To view the company’s Q1 earnings release, visit https://ibn.fm/NdrVh

About PayPal

PayPal has been revolutionizing commerce globally for more than 25 years. Creating innovative experiences that make moving money, selling, and shopping simple, personalized, and secure, PayPal empowers consumers and businesses in approximately 200 markets to join and thrive in the global economy. For more information, visit www.PayPal.com.

PayPal Holdings (PYPL), closed Tuesday's trading session at $59.71, off by 1.7443%, on 7,572,010 volume. The average volume for the last 3 months is 39,253 and the stock's 52-week low/high is $50.25/$76.54.

The QualityStocks Company Corner

Clene Inc. (NASDAQ: CLNN)

The QualityStocks Daily Newsletter would like to spotlight Clene Inc. (NASDAQ: CLNN).

CNM-Au8(R) works by improving cellular energy production and utilization, which is crucial for maintaining neuronal health

Clene has conducted several clinical trials to evaluate the safety and efficacy of CNM-Au8 in neurodegenerative diseases, including amyotrophic lateral sclerosis ("ALS")

The global ALS treatment market is expected to grow significantly, driven by the increasing prevalence of the disease among the aging population

Clene has submitted a briefing book to the FDA to seek feedback on a potential pathway for accelerated approval for CNM-Au8 to treat ALS

Clene (NASDAQ: CLNN), a biopharmaceutical company, is at the forefront of transforming the treatment of neurodegenerative disorders like ALS (amyotrophic lateral sclerosis) and multiple sclerosis ("MS"). In a recent Emerging Growth Conference 73 – Biotech Feature, Clene presented new findings and information pertinent to current and potential investors.

Clene Inc. (NASDAQ: CLNN) is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).

Its lead drug candidate is CNM-Au8®, an oral suspension developed to restore neuronal health and function by increasing energy production and utilization by driving critical cellular energy producing reactions that enable neuroprotection and remyelination to increase neuronal and glial resilience to disease-relevant stressors. CNM-Au8 is being studied in various clinical trials, including the Harvard/MGH Healey ALS Platform clinical trial for patients with ALS; RESCUE-ALS, a completed proof-of-concept clinical trial in patients with early symptomatic ALS; the REPAIR trials, completed target engagement clinical trials showing brain energy metabolite change with CNM-Au8; and a completed MS clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing MS. The company also has a nanotherapeutic platform of drug discovery.

CNM-Au8

CNM-Au8, Clene’s lead asset, is a highly concentrated aqueous suspension of catalytically active, clean-surfaced, faceted gold nanocrystals. Multiple pathogenic insults contribute to neuronal death. Mitochondrial dysfunction and NAD+ decline is a common final pathway in neurodegeneration, with NAD+ as a critical determinant of cell survival and function. CNM-Au8’s catalytic mechanisms target the energetic deficits, oxidative stress and accumulation of misfolded proteins that are common to many neurodegenerative diseases.

The unique catalytic mechanism of action of CNM-Au8 is hypothesized to act as a neuroprotective and remyelinating therapy in neurodegenerative disease states in order to: (1) drive, support and maintain beneficial metabolic and energetic cellular reactions within diseased, stressed and/or damaged cells, (2) directly catalyze the reduction of harmful, reactive oxygen species (“ROS”) and (3) promote protein homeostasis via activation of the heat shock factor-1 pathway, recognized to dampen the cytotoxicity caused by misfolded and denatured proteins, which are known to occur ubiquitously in neurodegenerative diseases.

CNM-Au8 is used in combination with other agents, has no known drug-drug interactions, and is designed to improve function and survival. The clinical effects of both function and survival were seen in its clinical ALS trials, as earlier announced.

More than 500 estimated years of collective exposure across ALS, MS, and Parkinson’s disease participants in CNM-Au8 clinical trials and Expanded Access Protocol (compassionate use) programs have been recorded without any observed safety signals.

CNM-Au8 is a federally registered trademark of Clene Inc. Clene, based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland, began in 2013.

Market Opportunity

ALS is the most prevalent adult-onset progressive motor neuron disease, affecting approximately 30,000 people in the U.S. and an estimated 500,000 people worldwide, with a life expectancy of typically three to five years. Clene estimates that global ALS treatment sales will be greater than $1 billion annually within the coming few years. Additional treatments affecting daily function and survival remain the market need.

Additionally, there are more than 2 million MS patients globally, and Clene estimates the market size to be worth more than $23 billion annually. While the MS community has been successful at limiting relapses, non-relapsing MS patients continue to clinically deteriorate even while receiving effective immunomodulatory disease-modifying therapies (“DMTs”). A critical unmet medical need remains for therapeutic interventions that protect neuronal function and myelin health independent of immunomodulation to address progression independent of relapse activity.

Management Team

Robert Etherington is President, Director and CEO of Clene. He has more than 30 years of sales, marketing and leadership experience in the pharmaceutical industry. Prior to joining Clene, he worked at Actelion Pharmaceuticals, the largest biopharma company in the European Union prior to its acquisition by Johnson & Johnson in 2017, where he led that company’s U.S. commercial operations. He began his pharmaceutical sales and marketing career at Parke-Davis, a division of Pfizer, where he rose to the position of Team Leader overseeing the drug Lipitor.

Mark Mortenson is Chief Science Officer at Clene. He is co-inventor of the technology platform developed to produce the company’s therapeutics. He is the inventor or co-inventor on 32 other U.S. patents and hundreds of corresponding international patents. He is a former chief patent counsel responsible for 5,500 U.S. and international patents and patent applications. He holds bachelor’s degrees in physics and ceramic engineering from Alfred University, a master’s degree in materials science from Penn State University and a J.D. from George Washington University.

Benjamin Greenberg, M.D., MHS, FAAN, is Head of Medical at Clene. He is an internationally recognized expert in disorders of the central nervous system. He is currently professor of neurology and Vice Chair of Clinical and Translational Research in the department of Neurology at University of Texas Southwestern Medical Center in Dallas. He holds a bachelor’s degree from Johns Hopkins, a master’s degree in molecular microbiology and immunology from the Johns Hopkins School of Public Health and graduated from Baylor College of Medicine. He served residency in neurology at The Johns Hopkins Hospital.

Morgan R. Brown is CFO at Clene. He has more than 30 years of finance and accounting experience, with 23 years at biotech, pharmaceutical and medical device companies. He has served in similar roles at Lipocine Inc., Innovus Pharmaceuticals, World Heart Corp., Lifetree Clinical Research and NPS Pharmaceuticals Inc. He previously worked at accounting firm KPMG. He is a CPA with a bachelor’s degree in accounting from Utah State University and an M.S. in business administration from the University of Utah.

Clene Inc. (NASDAQ: CLNN), closed Tuesday's trading session at $4.63, up 3.118%, on 39,349 volume. The average volume for the last 3 months is 2.091M and the stock's 52-week low/high is $4.23/$16.12.

Recent News

Annovis Bio Inc. (NYSE: ANVS)

The QualityStocks Daily Newsletter would like to spotlight Annovis Bio Inc. (NYSE: ANVS).

The new executive team includes Mark White, Alexander Morin, Hilda Maibach, and Blake Jensen

These additions are pivotal as the company makes strides toward bringing flagship drug candidate buntanetap closer to New Drug Application ("NDA") status and to market

Annovis Bio (NYSE: ANVS), a pioneering late-stage clinical drug platform company focusing on transformative therapies for neurodegenerative disorders such as Alzheimer's Disease ("AD") and Parkinson's Disease ("PD"), is thrilled to welcome four seasoned professionals to its executive team.

Annovis Bio Inc. (NYSE: ANVS) is a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s Disease (AD) and Parkinson’s Disease (PD). Annovis Bio stands out by developing a drug that targets multiple neurotoxic proteins simultaneously, aiming to restore axonal and synaptic activity. This innovative approach aims to treat memory loss and dementia associated with AD and body and brain dysfunction associated with PD, making Annovis a unique player in the neurodegeneration space.

Lead Drug Candidate: Buntanetap

Buntanetap (formerly Posiphen) targets neurodegeneration by inhibiting the formation of multiple neurotoxic proteins, including amyloid beta, tau, alpha-synuclein, and TDP43. This multifaceted inhibition improves synaptic transmission and axonal transport, reduces neuroinflammation, and protects nerve cells from dying. Unlike monoclonal antibody therapies, Buntanetap is an orally available small molecule capable of inhibiting multiple neurotoxic proteins at once, positioning it as a comprehensive solution for neurodegenerative diseases.

In a recent Phase II/III Alzheimer’s study, Buntanetap demonstrated statistically significant efficacy. Patients with early AD showed a significantly higher rate of improvement in ADAS-Cog 11 scores across all treatment doses compared to placebo, with a -3.3 point improvement compared to -0.3 for placebo (p < 0.01). Plasma Tau protein levels also reduced, consistent with previous Phase II biomarker data, further validating Buntanetap’s mechanism of action.

Similarly, in the Phase III study of Buntanetap in patients with early Parkinson’s disease, significant advancements were observed. Topline data results are anticipated in June 2024. Preliminary findings indicate promising results in improving cognitive and motor function, underscoring Buntanetap’s potential as a transformative therapy for Parkinson’s disease.

Market Opportunity

The aging population presents a significant market opportunity, with nearly 7 million Americans currently suffering from Alzheimer’s Disease (AD), a figure projected to rise to almost 13 million by 2050 (Alzheimer’s Association) (Republican Policy Committee). Additionally, approximately 1.2 million people in the U.S. have Parkinson’s Disease (SingleCare).

The economic burden of Alzheimer’s is immense, with care costs expected to reach $360 billion in 2024 and escalate to nearly $1 trillion annually by 2050. The need for effective, comprehensive treatments like Buntanetap is more critical than ever.

Company Highlights

  • Innovative Therapeutic Approach: Annovis Bio uniquely targets multiple neurotoxic proteins, aiming to restore nerve cell health and improve cognitive and motor function in AD and PD patients.
  • Robust Clinical Data: Phase II/III studies show significant improvements in cognitive function and biomarker levels in early AD patients.
  • Groundbreaking Clinical Insights: Preliminary results from Phase II studies indicate significant improvements in motor functions and speed in patients with Parkinson’s Disease (PD).
  • Upcoming Phase III Trials: Plans are underway for an 18-month Phase III trial focusing on biomarker-positive early AD patients, designed to further validate Buntanetap’s disease-modifying potential.
  • Capital Efficiency: Annovis Bio is capital-efficient, with zero debt and multiple global patents extending into the 2040s.

Management Team

Maria L. Maccecchini, Ph.D., Founder, President, CEO, and Executive Board Member, founded Annovis Bio in May 2008 with the mission to develop better therapeutics for Alzheimer’s, Parkinson’s, and other neurodegenerative diseases. She has previously been a partner and director at two angel groups, Robin Hood Ventures and MidAtlantic Angel Group, and founded Symphony Pharmaceuticals/Annovis, which was sold to Transgenomic in 2001. Her extensive experience includes roles such as General Manager at Bachem Bioscience and Head of Molecular Biology at Mallinckrodt. Dr. Maccecchini holds a Ph.D. in biochemistry from the Biocenter of Basel, with postdoctoral work at Caltech and the Roche Institute of Immunology.

Cheng Fang, Ph.D., Senior VP of Research and Development, is an accomplished neuroscientist with two decades of experience in neurodegenerative diseases. She has a successful track record of scientific publications and contributions, coupled with extensive pre-clinical and clinical development experience. Dr. Fang has been instrumental in advancing the understanding of neurodegenerative disease mechanisms and developing therapeutic strategies.

Michael Christie, Ph.D., VP of Process Chemistry, has over 40 years of experience in the pharmaceutical industry, focusing on process chemistry R&D, pilot plant production, and GMP operations. He has held senior management positions at companies such as SmithKline, Rhodia, Teva, and Cephalon, and founded a contract process R&D service company, which was later acquired by ChiRex. Dr. Christie is co-author or co-inventor on several publications and patents. He earned his BS in chemistry from the University of Michigan and his doctorate from MIT.

Melissa Gaines, Senior VP of Clinical Operations, is an accomplished clinical research professional with over 20 years of experience across academia, contract research organizations, and pharmaceutical companies. She has proven abilities in monitoring and managing Phase I to IV clinical trials, specializing in CNS disorders and extending to a broad range of therapeutic indications. Her CNS experience spans from small Phase I and II studies to large global Phase III trials in Alzheimer’s disease, Parkinson’s disease, sleep disorders, and various psychiatric diseases in both adult and pediatric populations. In her current role, she oversees and supports all clinical project activities, driving operational success and ensuring high-quality clinical outcomes.

Learn more about the Annovis Bio team on LinkedIn.

Annovis Bio Inc. (NYSE: ANVS), closed Tuesday's trading session at $10.65, off by 0.9302326%, on 284,865 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $16.12/$.

Recent News

FingerMotion Inc. (NASDAQ: FNGR)

The QualityStocks Daily Newsletter would like to spotlight FingerMotion Inc. (NASDAQ: FNGR) .

Germany is considering banning Chinese telecommunications companies from accessing its nascent 5G network. A recent statement from the German government revealed that the European economic giant will spend the next few years phasing out the use of parts developed by Chinese telecom companies ZTE and Huawei from its 5G network due to security concerns. This will mark the second time a major Western economy has turned an unfavorable eye toward Huawei after the Trump administration booted it out of the United States. This time, however, it seems another Chinese telecommunications company will also be caught in the crossfire. The move by Berlin also represents German efforts to reduce the country's reliance on Chinese companies across various critical industries. With China largely dominating the global electric vehicle supply chain, Germany may be unwilling to let itself become reliant on China in 5G as well. The decision to push Huawei and ZTE out of Germany's 5G network comes after the European Union warned that the two companies posed a security risk to member nations. Although Faeser did not comment on whether China would retaliate against the move, she said Beijing already knew about the ZTE and Huawei bans. Huawei has argued that there was "no specific evidence" associating its 5G technology with cyber security risks while the Chinese embassy in Berlin said the move was based on "groundless accusations." It would be interesting to hear what companies that have interests within the telecommunications industry, such as FingerMotion Inc. (NASDAQ: FNGR), have to say about the suspicion with which telecommunication equipment from Chinese companies is being regarded in different markets.

FingerMotion Inc. (NASDAQ: FNGR) is an evolving technological company with core competencies in mobile payment and recharge platform solutions in China. FingerMotion is in the process of developing additional value-added technologies to market to users.

Founded in 2016, FingerMotion’s goal is to serve over a billion users in the Chinese market and expand its model to other regional markets. The company has offices in Hong Kong, Shanghai and New York City.

Current Offerings

FingerMotion is analyzing and transforming mobile data to improve the lifestyle of the public through technology and innovation. The company’s current offerings include:

  • Telecommunications Products and Services – FingerMotion’s proprietary universal exchange platform, ‘PigeonHole Integration System (PIS)’, offers seamless integration between telecom operators and online stores. The service platform’s offerings include top up and recharge, data plan, mobile phone, loyalty points redemption and subscription plans. The platform offers reliable and secure transactions, real-time reconciliation, simple integration for partners and efficient settlements.
  • SMS and MMS Services – The integrated platform is registered as FingerMotion’s IP in China and provides a robust back-end control panel for corporate partners to manage their own messaging settings. FingerMotion’s clients range from insurance to financial industries, ecommerce firms, airlines and more. The platform offers competitive pricing for partners and provides quick and efficient review to meet timely marketing initiatives.
  • Big Data Insights – FingerMotion brings Big Data-enabled insurance solutions through its Big Data Insights arm, Sapientus. The company’s strategic partnerships with the largest Chinese telecommunications giants allow access to uncover behavior insights through geolocation and mobile data usage. Its Big Data offerings include risk scoring, precise marketing, simplified underwriting and customized products.
  • Rich Communication Services (RCS) – FingerMotion’s RCS platform will be a proprietary business messaging solution that enables businesses and brands to communicate their services to customers via 5G infrastructure. The company expects its RCS platform to offer a better user experience, more efficiency and cost-effectiveness when compared to other solutions.

Telecommunications and Insurtech Markets

The global telecommunications market was valued at $1.74 trillion in 2019 and is expected to grow at a CAGR of 5% from 2020 to 2027. The steady increase is expected to be driven by the adoption of 5G and the increased popularity of Internet of Things (IoT) applications.

The Chinese telecom market was valued at $254.1 billion in 2017 and is also constantly expanding. The current Chinese telecom market is dominated by three mobile operators – China Mobile, China Unicom and China Telecom, which together are responsible for around 1.6 billion active subscribers (https://ibn.fm/zfwy9).

In addition, the insurtech (insurance technology) market was valued at $2.72 billion globally in 2020 and is expected to grow at a CAGR of 48.8% from 2021 to 2028. The large increase is attributed to the rising use of technology solutions for everyday activities like acquiring insurance coverage (https://ibn.fm/TGo7D).

Through its proprietary platforms and technologies, FingerMotion is uniquely positioned to capitalize on the telecom and insurtech markets’ growth and opportunities.

Management Team

Martin J. Shen is the Chief Executive Officer of FingerMotion Inc. He has over 15 years of experience in senior management roles within entrepreneurial startups and large multinational corporations. He has acquired a wide range of corporate management, financial oversight and operation administration expertise through these roles. In his most recent role, he founded Imperial Distributors (formerly known as AP Martin Pharmaceutical Supplies Ltd.), establishing the company as the preferred choice for distributional support to regional pharmacies throughout Western Canada. Before founding Imperial, Mr. Shen served as the Chief Operating Officer and Chief Financial Officer at Wales and Son Industrial (formerly Weir Minerals), a firm specializing in global delivery and support for mining slurry equipment. He began his career at PricewaterhouseCoopers in Vancouver, with work tours in the tax department in Singapore and the tax audit and advisory group in Hong Kong. Mr. Shen is a U.S. Certified Public Accountant and holds a Bachelor of Science from the University of British Columbia.

Lee Yew Hon is the company’s Chief Financial Officer. From 2006 until November 2020, he was the Chief Financial Officer of Cubinet Interactive Group of Companies, and he also took on the Chief Operating Officer role in 2011. During his tenure, he was instrumental in leading Cubinet and building teams across the Southeast Asia region, setting up financial processes within a short time. Mr. Lee spearheaded the growth of Cubinet to other regions, including Europe, the Middle East and Russia. He received his diploma from Tunku Abdul Rahman College in 1996. He is a Chartered Accountant, a member of the Malaysia Institute of Accountants (MIA) and an Associate Member of the Chartered Institute of Management Accountants, UK (ACMA).

Li Li is the Senior Vice President of FingerMotion. She recently served as Advisor to Shenzhen WuYiKa Technology Co. Ltd., a comprehensive service platform dedicated to online service distribution and payment. The company has become a fast and efficient provider of new media marketing solutions for the mobile internet. She has held high-level management positions with multiple industry names, including Hangzhou JiuYue Information Technology Co. Ltd. and Hangzhou LingXuan Information Technology. Ms. Li started her career in 2004, founding Shanghai ChuangYeZZ Network Technology Co. Ltd. and serving as its Vice President. With the close cooperation of local operators, the company launched SMS, MMS, WAP, mobile JAVA games, Hunan Satellite TV e-magazine and other wireless internet services to meet the rapid development of wireless internet and application requirements. She received her degree from Nanjing Academy of Engineering.

FingerMotion Inc. (FNGR), closed Tuesday's trading session at $2.02, up 2.0202%, on 212,209 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $1.85/$7.97.

Recent News

Horizon Fintex | Upstream

The QualityStocks Daily Newsletter would like to spotlight Horizon Fintex | Upstream

Constellation Network Inc. has continued bringing trailblazing innovations in the digital space by announcing its first-ever global Web3 Hackathon, set against the backdrop of emerging technologies such as Constellation Network's Hypergraph. The event, which began on July 15 and will run until Sept. 9, 2024, is expected to be a game-changer in the world of decentralized technology. Constellation's Hypergraph, which was developed under U.S. Department of Defense contracts, serves as a foundational layer for diverse blockchain applications. These are known for their fast and feeless transactions facilitated by Directed Acyclic Graph (DAG) architecture. Features include scalability, security and simplified integration, making it a great option for businesses and governments exploring blockchain solutions. This platform is now open for the public to use. The initiative from Constellation has gained support from various companies, including Panasonic, IBM and others; it has also received institutional backing from the National DigiFoundry. These industry experts and the world at large believe in the hackathon's potential to propel forward interoperability and collaboration across the blockchain ecosystem. Ben Jorgensen, Constellation Network CEO, believes Hypergraph to be the "blockchain of blockchains," stressing its capability to unify disparate technologies. This hackathon is likely to be closely watched by businesses that use Web3 technology, such as Horizon Fintex, since their next solution could be hatched during this event.

Horizon Fintex is a software business specializing in compliant securities solutions. The company aims to facilitate the future of capital markets by leveraging the regulatory experience of Wall Street bankers and the proven track record of technology veterans to bring focus to compliance, efficiency, security and transparency.

Horizon’s flagship product is the revolutionary trading app ‘Upstream’, a MERJ Exchange Market, and the first regulated market powered by a blockchain to offer both digital securities and NFT trading. Upstream traders experience T+0 settlement, best bids and offers displayed on a transparent public orderbook that prevents predatory market practices – all from a user-friendly trading app.

Products

Horizon Fintex offers a full suite of end-to-end blockchain-enhanced software solutions to create a seamless experience for both issuers and investors. Its product suite includes:

  • Securitization & IssuanceETSware is an end-to-end Electronic Trading System streamlining capital raising from primary issuance through compliant secondary trading.
  • KYC Compliance OnboardingKYCware is a white label Know Your Customer (KYC) and Anti-Money Laundering (AML) compliance software solution offering best-in-class cryptographic security to compliantly onboard and verify user identity through a smartphone application.
  • AML Screening SoftwareAMLCop offers advanced Anti-Money Laundering (AML) software to streamline the verification of user details against a proprietary database of global sanctions, politically exposed persons (PEPs) and watchlists.
  • Cap. Table Management ToolsCustodyWare equips registered U.S. transfer agents with next-generation cap. table management software to manage securities on behalf of their clients pursuant to an SEC-registered or exempt securities offering.
  • Exchange & Trading App TechnologyOpen Order Book offers Ethereum blockchain securities exchange software to power the next generation of trading venues for digital assets.

Upstream – The Horizon-Powered Trading App

Upstream is a joint venture with MERJ Exchange (merj.exchange), an affiliate of the World Federation of Exchanges.

Upstream aims to be the premiere global trading hub offering issuers around the world exposure to a digital-first investor base that can trade using USDC digital currency along with credit, debit, PayPal, and USD (fiat) to increase liquidity and enhance price discovery; while also offering investors access to dual-listed companies, IPOs, crowdfunded companies, U.S. & Int’l. equities, digital coupons and NFTs directly from a user-friendly trading app.

Upstream aims to unlock liquidity for investors of all levels while offering industry-leading levels of transparency, accessibility and investor protections enforced using Ethereum blockchain technology.

Management Team

Brian Collins is the CEO of Horizon Fintex. He founded the company in 2010. From 1999-2010, Mr. Collins was CEO of Abbey Technology in Switzerland, specializing in the design of trading software for Swiss banks. Prior to this, he worked for Credit Suisse in Zürich, designing and building proprietary equity trading solutions. Mr. Collins graduated in 1990 with a BS in Computer Systems from the University of Limerick, Ireland.

Mark Elenowitz is the company’s President. He is a Wall Street veteran with over 29 years of experience. Mr. Elenowitz was the co-founder of a U.S. broker dealer and is Managing Director of two U.S. broker dealers, responsible for advising clients on compliance, capital structure and capital market navigation. He was responsible for leading the first successful Reg A+ IPO of a company to list on the NYSE and others which listed directly onto Nasdaq. He is a noted speaker at Small Cap and Reg A events, including the SEC Small Business Forum, and has been profiled in BusinessWeek and CNBC, as well as several other publications. Mr. Elenowitz is a graduate of the University of Maryland School of Business and Management with a BS in Finance and holds Series 24, 62, 63, 79, 82 and 99 licenses.

Dr. Andrew Le Gear is the CTO of Horizon Fintex. Prior to joining the company in 2013, he worked as a software engineer with Dell Inc. (2012-2013) and Lehman Brothers and Nomura Plc. (2007-2012). Dr. Le Gear was a co-founder of Juneberi Ltd., a research-driven software tech start-up (2004-2007). He graduated in 2006 with a Ph.D. in Computer Science from the University of Limerick, Ireland.

Peter Hall is the company’s CIO. Prior to joining Horizon Fintex in 2011, he worked at Microsoft (2008-2011), Atos Origin (2004-2008) and AIT Group Plc. (1998-2002). Mr. Hall has held CISSP certification since 2010. He graduated from the University of Sheffield, UK in 1995 and earned an MS from the University College London in 2006.

Mike Boswell is the CFO of Horizon Fintex. A Wall Street veteran, he co-founded a U.S. broker dealer and served as Chief Compliance Officer. Mr. Boswell was also Managing Director of TriPoint Capital Advisors, a merchant banking and financial consulting company, and CFO of Mission Solutions Group, a privately held defense sector firm. He earned an MBA from John Hopkins University and a BS in Mechanical Engineering from the University of Maryland. Mr. Boswell holds Series 24, 62, 63, 79, 82 and 99 licenses.

Recent News

chart

Mullen Automotive Inc. (NASDAQ: MULN)

The QualityStocks Daily Newsletter would like to spotlight Mullen Automotive Inc. (MULN).

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle ("EV") manufacturer, has announced that its subsidiary, Bollinger Motors, released its full warranty coverage on the Bollinger B4 Chassis Cab, the company's all-new, all-electric Class 4 commercial truck. "We have designed and engineered the Bollinger B4 to have unmatched capability and durability, and we are proud to be offering warranty coverage to reflect that," said Jim Connelly, chief revenue officer of Bollinger Motors. "Our warranty provides our customers the peace of mind they need in making their decision and demonstrates the confidence we have in the B4."

To view the full press release, visit https://ibn.fm/qU9HZ

Mullen Automotive Inc. (NASDAQ: MULN) is a Southern California-based automotive company that owns and partners with several synergistic businesses working toward the unified goal of creating clean and scalable energy solutions. Mullen has evolved over the past decade in sync with consumers and technology trends. Today, the company is working diligently to provide exciting EV options built entirely in the United States and made to fit perfectly into the American consumer’s life. Mullen strives to make EVs more accessible than ever by building an end-to-end ecosystem that takes care of all aspects of EV ownership.

Commencement of Trading on Nasdaq

On November 5, 2021, Mullen announced its commencement of trading on the Nasdaq Capital Market.

“Today is a monumental day for Mullen Automotive. I am especially proud of our team, investors and all who have believed in Mullen and taken us to this point as a publicly traded company on the Nasdaq Capital Market,” David Michery, CEO and Chairman of Mullen Automotive, stated in the news release. “Trading on Nasdaq now opens us up to new investors, both institutional and retail shareholders, and broadens our awareness and company profile, while increasing awareness of Mullen and our technology platform and opening new opportunities in EV and beyond. The road ahead has never been brighter for Mullen, and I am proud to lead us into the future.”

The milestone came in the wake of the company’s stock-for-stock merger with Net Element Inc.

The Mullen FIVE

The Mullen FIVE EV Crossover, debuting at the Los Angeles International Auto Show (LAIAS) on November 17, 2021, embodies Mullen’s Southern California roots with an inspired design focused on two complementary Golden State themes – California landscape and California urban.

The FIVE is built on an EV Crossover skateboard platform that offers multiple powertrain configurations and trim levels in a svelte design that is Strikingly Different™ and exciting to experience in person.

Prior to the start of LAIAS, the Mullen FIVE was selected as a finalist by the LA Auto Show for Top EV SUV in the ZEVA “People’s Choice” Awards.

LAIAS provides Mullen an opportunity to display multiple variants of the FIVE model while also showcasing its powertrain, battery and charging technology. The company intends to bring the FIVE to market in 2024, and reservations are currently open here.

Mullen’s development portfolio also includes EV Fleet Vans, which it intends to bring to market in Q2 2022, and the pure electric, high performance Mullen DragonFLY.

Expansion of Manufacturing Capacity

On November 2, 2021, Mullen announced plans to expand its facility in Robinsonville, Mississippi.

Mullen’s Advanced Manufacturing and Engineering Facility (AMEC) currently occupies 124,000 square feet of manufacturing space. The total available land on the property is over 100 acres, and Mullen is moving ahead with plans to build out another 1.2 million square feet of manufacturing space to support class 1 and class 2 EV cargo vans and the Mullen FIVE EV Crossover.

On the expanded site, Mullen plans to build a body shop, a fully automated paint shop and a general assembly shop.

EV Market Outlook

The global EV market was reported to consist of 3,269,671 units in 2019, a figure that is expected to grow at a CAGR of 21.1% through 2030 to a total of 26,951,318 units worldwide. This market’s monetary value was estimated at $162.34 billion in 2019 and is expected to grow at a CAGR of 22.6%, resulting in an approximate value of $802.81 billion by 2027. The primary driver for this exponential growth is a worldwide increase in vehicle emissions regulations.

Management Team

David Michery is the CEO and Founder of Mullen and has been leading the company and its divisions since inception in 2014. With over 25 years of executive management, marketing, distressed assets, and business restructuring experience, Mr. Michery brings a wealth of relevant knowledge and expertise to the Mullen brand. He has notably created 12 trademarks so far to develop the company brand and vision.

Mr. Michery is working toward a sustainable future accessible to all by creating a suite of clean-energy electric vehicles at varied price points. With entirely U.S.-based manufacturing and operations, he is also determined to have Mullen Technologies play a role in shaping a self-sustaining local economy by creating more jobs in America.

Mr. Michery manages risks and company expectations as a pathway to success and has personally overseen several businesses that totaled over $1 billion in transactions. His key strength is the ability to be fiscally responsible and lead teams to complete projects on time and within budget. As a seasoned professional in this space, Mr. Michery has demonstrated skill in building businesses from the ground up and into successful entities that subsequently sold for hundreds of millions of dollars.

Mullen Automotive Inc. (MULN), closed Tuesday's trading session at $1.37, off by 3.5211%, on 3,116,404 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $1.33/$155.70.

Recent News

Reflex Advanced Materials Corp. (CSE: RFLX) (OTCQB: RFLXF)

The QualityStocks Daily Newsletter would like to spotlight Reflex Advanced Materials Corp. (CSE: RFLX) (OTCQB: RFLXF).

Reflex Advanced Materials Corp. (CSE: RFLX) (OTCQB: RFLXF) is a strategic minerals company focused on locating and developing economic properties in the strategic metals and advanced materials space. The company aims to improve domestic specialty mineral infrastructure efficiencies to meet surging national demand from North American manufacturers, effectively positioning itself as one of the only North American suppliers of high purity natural graphite for hi-tech applications.

Reflex Advanced Materials is based in Vancouver, British Columbia. Its project portfolio includes the Ruby Graphite Deposit in Montana and the ZigZag Lithium Property in Ontario.

Projects

Ruby Graphite Project

Located in a mining-friendly jurisdiction in southwest Montana, the Ruby Graphite Deposit is a low cost, rapid re-entry opportunity that produced roughly 2,400 tons of graphite from 1902 to 1948. Reflex Advanced Materials holds mining rights for 755 hectares at the Ruby Graphite Project, with 96 federal lode mining claims. Recent samples assay at 95.8% to 98.4% total carbon.

The site is notable as the only combined U.S. graphite flake and vein graphite source. Vein graphite is ideal for energy storage applications, because it requires fewer steps to achieve purity than synthetic alternatives and is therefore far less environmentally damaging. This is expected to play a key role in the project’s development as demand for electric vehicles continues to surge.

In March 2023, the company announced its submittal of permit applications to the Bureau of Land Management in respect of its exploration of the Ruby Graphite Project. Its initial drill program, expected to take place in the summer of 2023, includes plans for 3,500 total meters of drilling, cored to an average depth of 130 meters. The targets for this drill program have been identified using historical data from original mine operations and data gathered for the initial 43-101 technical report on the project, dated January 31, 2023.

ZigZag Lithium Property

Located in the Thunder Bay Mining Division of Ontario, the ZigZag Lithium Property consists of eight mining claims spanning roughly 2,710 hectares. Mineralization at the property, most notably lithium, is based in pegmatite dikes and concentrated in spodumene crystals, which are consistent throughout the entire unit.

Spodumene is readily observable in outcrops and in drill cores, with crystal sizes ranging from 3-15cm, on average.

Reflex Advanced Materials and American Energy Technologies Company Metallurgical Partnership

Reflex Advanced Materials has entered into a material processing agreement with American Energy Technologies Co., which is based in Arlington Heights, Illinois, to conduct metallurgical testwork with the goal of creating a technical support data package for Reflex’s target customer base, U.S. Federal agencies and qualification programs with hi-tech customers in the battery and battery storage business.

The resulting coated, spherionized, purified graphite (CSPG) material that is expected to be created from the aforementioned tests will be used to provide potential customers of CSPG with samples so that they can begin the material qualification process.

Market Opportunity

Graphite is an ideal battery anode and has dominated the market since the proliferation of lithium-ion batteries. Despite this demand, there is currently no significant production of lithium-ion battery anode material in North America.

Instead, most graphite sold in North America today is sourced from Chinese producers. U.S. President Joe Biden highlighted this sourcing disparity in a 2022 address:

“The United Stated depends on unreliable foreign sources for many of the strategic and critical materials necessary for the clean energy transition – such as lithium, nickel, cobalt, graphite and manganese for large-capacity batteries,” he said. “Demand for such materials is projected to increase exponentially as the world transitions to a clean energy economy.”

The U.S. Department of Energy is in the process of awarding $2.8 billion to expand domestic manufacturing of batteries for electric vehicles and combat this foreign dependency. Reflex Advanced Materials has identified its Ruby Graphite Project as a prime candidate for U.S.-sponsored initiatives due to the rarity and scarcity of natural graphite deposits in the country.

Processing graphite domestically in the U.S. is expected to provide Reflex Advanced Materials a competitive advantage as manufacturers begin to seek out American supply in the face of increased diplomatic tension. This is critical, as a rise in anode demand is expected to fuel a shortage of 8 million tonnes of graphite by 2040. World Bank Group projects 494% growth in total graphite demand by 2050.

Leadership Team

Paul Gorman is the CEO and a Director of Reflex Advanced Materials. He brings to the company over 25 years of experience in junior mining finance, public listings, viability assessment and operational rationalization. For 18 years, Mr. Gorman served as president and managing partner of Riverbank Capital, where he played an instrumental role in raising more than $85 million for small-cap companies. In 2008, he funded Industrial Minerals Inc. (later Northern Graphite) and served in an advisory role for four other graphite companies, contributing significantly to the revitalization of the junior graphite space in North America. Mr. Gorman founded Mega Graphite Inc. in 2009 and has served as chief executive for three other companies.

Tasheel Jeerh, CPA, is the company’s CFO. He is a finance and accounting professional with over a decade of experience spanning both public and private sectors. Prior to joining Reflex Advanced Materials, Mr. Jeerh played a pivotal role in the growth of a private upstream oil and gas firm, dealing with over $2 billion in M&A activity and $1 billion in financing activities. He gained his designation at PricewaterhouseCoopers, where he worked as a manager in the assurance practice.

Greg Bell is Project Manager for Reflex Advanced Materials. He is a multi-disciplined engineering management professional with more than 40 years of experience in the natural resources sector. Mr. Bell has successfully built and managed several start-up operations in various capacities. He has been active in graphite and lithium exploration for the past seven years.

Christopher W. Hill leads the company’s Corporate Development initiatives. He is an investor and entrepreneur with over a decade of experience in the capital markets. Mr. Hill began his career as an investment advisor and then began to consult and advise private companies on their paths to becoming publicly traded. He specializes in corporate development and strategic financing utilizing his large network in the capital markets.

Reflex Advanced Materials Corp. (RFLXF), closed Tuesday's trading session at $0.04055, even for the day, on 42 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.0306/$0.35.

Recent News

ECGI Holdings Inc. (OTC: ECGI)

The QualityStocks Daily Newsletter would like to spotlight ECGI Holdings Inc. (OTC: ECGI).

ECGI Holdings Inc. (OTC: ECGI) is a diversified holding company with a distinctive portfolio encompassing viticulture and luxury fashion. The company owns and manages a five-acre vineyard in Lake County, California, specializing in cultivating the Petite Sirah varietal, known for its bold and rich character, aligning with the growing demand for unique and high-quality wine experiences.

In the fashion sector, ECGI has strategically invested in Pacific Saddlery, a premier manufacturer and retailer of luxury equestrian tack, apparel and accessories. This unique blend of wine and fashion investments reflects ECGI Holdings’ commitment to delivering sophistication and innovation across diverse markets, positioning the company as a distinctive player in the intersection of technology, viticulture and luxury lifestyle.

Moving forward, ECGI Holdings is focused on identifying and capitalizing on growth opportunities that align with the company’s business objectives and continuing to improve its financial structure. In 2024, ECGI Holdings was approved by Evolve — a distinguished name in vacation rental management. This partnership will transform the company’s 40-acre Lake County property into a luxurious short-term rental destination aptly named Vintner’s Caldera Ranch.

ECGI Holdings is excited about the possibilities that Vintner’s Caldera Ranch creates for shareholders and looks forward to further developments poised to unlock the value of other underutilized assets. The company believes that it is laying a solid foundation for sustained success and profitability in the years to come.

ECGI Holdings is headquartered in Irvine, California.

Operational Philosophy

ECGI Holdings has embarked on an ambitious new vision and strategic direction to build and nurture luxury brands that resonate with its core values and market aspirations. Its joint venture with Pacific Saddlery epitomizes ECGI Holdings’ strategic shift toward luxury branding, leveraging Pacific Saddlery’s tangible and established market presence in equestrian products.

This transition will also allow ECGI Holdings to explore new pathways to monetize its underutilized assets, including the company’s vineyard. A key highlight of the company’s future outlook is the debut of Pacific Saddlery’s new mobile retail boutique at specific equestrian events in 2024. This innovative venture represents a significant step in ECGI Holdings’ strategy to enhance brand visibility and engage directly with the company’s target market.

In addition, the Vintner’s Caldera Ranch development marks a significant step in advancing the company’s strategy to revitalize and leverage underutilized assets. Vintner’s Caldera Ranch is set against the backdrop of Lake County’s breathtaking scenery, offering an exclusive getaway experience that blends natural beauty with luxury. Choosing Evolve is a strategic move to ensure that Vintner’s Caldera Ranch not only meets but exceeds the high standards of service that luxury guests expect.

Evolve’s expertise in maximizing rental potential and delivering exceptional guest experiences is crucial to the company’s vision of making Vintner’s Caldera Ranch a preferred choice for discerning travelers. With this venture, ECGI Holdings is not only expanding its footprint within the luxury rental marketplace, but also contributing to the local economy and enhancing the appeal of Lake County as a tourist destination.

The company’s focus remains steadfast on strategic growth, operational excellence and customer satisfaction.

Market Outlook

A report from Grand View Research, a global market research and consulting company, estimated the value of the worldwide luxury brands market at $366.23 billion in 2023 and projects the market to grow to a value of $580.43 billion by 2030, achieving a CAGR of 6.8% over the forecast period.

Rising disposable income and wealth in various regions of the world, particularly in emerging markets such as China and India, have propelled the growth of the market, according to the report.

Younger consumers, such as millennials and Generation Z, are increasingly entering the luxury market, driving demand for more contemporary and experiential luxury offerings. The rise of social media and influencer marketing has greatly impacted the visibility and desirability of luxury products, the report states.

Management Team

Jamie Steigerwald is CEO of ECGI Holdings, Inc. He is a successful entrepreneur with over 30 years of experience. Most recently, he was COO of Sugarmade Inc. (OTC: SGMD), a California cannabis real estate, cultivation, manufacturing and services company. He is the owner of SwiftLead, an Orange County web marketing, design and development company. He previously was COO for First USA Home Loans, a retail mortgage lender, and co-founder and President of SwiftLead Software, a mortgage lead tracking system.

Nick Collins is CEO at Pacific Saddlery. He brings over 25 years of expertise in equestrian luxury goods. He previously founded Rolling Meadows and created the Allon Equestrian and Renard et Cheval apparel brands. He was instrumental in creating and launching Kaval.com, an online equestrian apparel and accessories site.

ECGI Holdings Inc. (OTC: ECGI), closed Tuesday's trading session at $0.0029, even for the day. The average volume for the last 3 months is and the stock's 52-week low/high is $0.0016/$0.015.

Recent News

Nightfood Holdings Inc. (OTCQB: NGTF)

The QualityStocks Daily Newsletter would like to spotlight Nightfood Holdings Inc. (OTCQB: NGTF).

Nightfood Holdings Inc. (OTCQB: NGTF) is a visionary holding company focused on identifying and capitalizing on explosive market trends within hospitality, food services and consumer packaged goods. By leading newly emerging categories and seizing opportunities in markets undergoing transformational upheaval, the company’s mission is to create unparalleled upside potential in industries ripe for innovation and growth.

Subsidiaries

Nightfood Inc.

The company’s flagship subsidiary, Nightfood Inc., is changing the way the world snacks at night. Humans are biologically hard-wired to crave sweets and fats at night – a survival mechanism from our hunter-gatherer days. Modern consumers know bingeing excess calories before the long nightly fast is no longer necessary for survival, but exploding screen time and decreased willpower at night results in over 90% of American adults snacking between dinner and bed every week, contributing to an estimated one billion nighttime snack occasions weekly (according to SleepFoundation.org).

The most popular choices – ice cream, cookies, chips and candy – are not only unhealthy but also impair sleep quality due to their nutritional profiles. Nightfood snacks are uniquely formulated by sleep and nutrition experts to satisfy nighttime cravings AND support better sleep.

Market Opportunity

Euromonitor International projects the American snack market will grow from $150 billion in 2022 to $170 billion in 2027. Snacking between dinner and bed is estimated to account for over $60 billion annually, creating an opportunity for a multi-billion-dollar sub-category to emerge in the coming years: sleep-friendly snacking.

Nightfood is the brand pioneering that category.

Nightfood’s innovation has led to partnership overtures from global giants, including the largest food and beverage company in the world, Nestlé, with whom Nightfood completed a “test-and-learn” joint initiative in 2023.

Management believes that successfully scaling Nightfood’s 2024 direct-to-consumer launch of sleep-friendly cookies will bring the category to life, opening the door for partnerships with and potential acquisition by global snack giants seeking to lead this potential billion-dollar emerging sub-category.

Future Hospitality Ventures Holdings Inc. (d/b/a roboOp365)

Future Hospitality Ventures Holdings, operating under the brand roboOp365, is revolutionizing the hospitality industry with cutting-edge automation and robotic solutions.

roboOp365 enhances operational efficiency and guest experiences through innovative technologies, including automated culinary bot, server robots and AI-enhanced applications. roboOp365 helps hospitality providers reduce costs, streamline operations and deliver superior service by integrating these advancements.

Market Opportunity

The robots-as-a-service (RaaS) business model has gained significant traction, super-charged by the COVID-19 pandemic, which instantly catalyzed game-changing growth and application. According to Verified Market Research, the service robotics market is projected to reach $173.17 billion by 2030, growing at a compound annual growth rate (CAGR) of 21.25%. Compared to Asia, the United States market is in the early stages of adopting these technologies, but acceptance is accelerating aggressively.

Several factors are driving this trend. Key industries such as hotels and restaurants are still struggling to rebound from the pandemic’s impact, hoping to return to pre-pandemic levels, if possible. Such recovery will largely be dependent upon service robots. In California specifically, factors such as rising labor costs, more rigorous labor laws and ongoing high turnover rates in labor-intensive sectors make it impossible for businesses to survive, thrive and compete without robotics.

Innovation Across Sectors

Nightfood Holdings Inc. is dedicated to driving innovation across its focus sectors of food services, automation and hospitality applications. In food services, the company leverages automation technology to drive operational efficiency for operators while meeting evolving consumer needs. In the hospitality industry, it’s deploying solutions that redefine guest experiences. Nightfood’s consumer-packaged goods initiatives are key to breakthrough trends in health and wellness.

Synergizing Food and Technology

The synergy of food and technology within Nightfood Holdings Inc. creates a holistic approach to innovation and automation. By integrating these areas, the company offers comprehensive solutions that address multiple facets of market needs. Its automation and artificial intelligence solutions in food service and hospitality create a seamless and enhanced consumer experience.

Through this integrated approach, Nightfood Holdings Inc. not only meets current market demands but also anticipates and influences future trends, positioning itself as a leader in innovation across these interconnected sectors. Synergies in these related and explosive categories result in operational efficiency and benefits for the company’s customers and partners and outsized upside and opportunity for its investors.

Management Team

Sean Folkson is the Chairman and President of Nightfood. He founded Nightfood when he couldn’t find a solution to his nighttime snacking problem. Recognizing the growing body of research linking nutritional intake with sleep quality, he launched the first snack brand specifically formulated to give consumers better, healthier and more sleep-friendly snacks for that peak-cravings slot between dinner and bed. He is a serial entrepreneur and problem-solver, having previously founded Specialty Equipment Direct, an online distributor of floor removal equipment, and AffiliatePros.com, a pioneering company in online affiliate marketing.

Lei Sonny Wang is the CEO of Nightfood Holdings. He is a strategist and business driver for early-stage and growth-stage companies. He is the founder and former CEO of Future Hospitality Ventures Holdings Inc., which was acquired by Nightfood Holdings Inc. At Future Hospitality, he leveraged his significant international business development experience into distribution relationships with leading global robotics manufacturers. At Nightfood, he is working to grow revenue and improve performance and profitability across all subsidiaries.

Nightfood Holdings Inc. (OTCQB: NGTF), closed Tuesday's trading session at $0.0239, up 8.6364%, on 10,882 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.0075/$0.0425.

Recent News

D-Wave Quantum Inc. (NYSE: QBTS)

The QualityStocks Daily Newsletter would like to spotlight D-Wave Quantum Inc. (NYSE: QBTS).

D-Wave Quantum Inc. (NYSE: QBTS) is a leader in quantum computing systems, software and services focused on delivering customer value via practical quantum applications for problems such as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, fault detection and financial modeling. As the only provider building both annealing and gate-model quantum computers, the company is unlocking commercial use cases in optimization today, while building the technologies that will enable new solutions tomorrow.

D-Wave is a pioneer in quantum computing, with a history of delivering the world’s first commercial quantum computer; the first real-time quantum cloud service; countless hardware and software product and research milestones; and the planned first cross-platform quantum solution which will deliver both annealing and gate-model quantum computers to customers via an integrated platform. Its current commercial product offerings include: Advantage™ (fifth generation quantum computer), Leap™ (quantum cloud service), Launch™ (quantum computing onboarding service) and Ocean™ (full suite of open-source programming tools).

D-Wave’s relentless pursuit of practical quantum computing has resulted in the technology being used today by some of the world’s most advanced enterprises – more than 25 of the Forbes Global 2000 use D-Wave.

D-Wave’s commercial customers include blue-chip industry leaders like Volkswagen, Accenture, BBVA, NEC Corporation, Save-On-Foods, DENSO and Lockheed Martin. The company boasts an extensive IP portfolio featuring more than 200 issued U.S. patents and over 100 peer-reviewed papers published in leading scientific journals.

Founded in 1999, D-Wave is the world’s first commercial supplier of quantum computers. With headquarters and the Quantum Engineering Center of Excellence based near Vancouver, Canada, D-Wave’s U.S. operations are based in Palo Alto, California.

Advantage™ Quantum Computer

 

With the Advantage™ Quantum Computer, D-Wave has incorporated two decades of experience and over 10 years of customer feedback to create the first and only quantum computer designed for business. The platform features a new processor architecture with over 5,000 qubits and 15-way qubit connectivity. This is 2.5x more connections and more than double the number of qubits than the company’s previous generation quantum computer.

D-Wave’s quantum computers, first located in its facilities in British Columbia, have been available to North American users through its Leap™ quantum cloud service since 2018. It has since introduced new Advantage systems in Julich, Germany, and most recently, Marina Del Rey, California, which marked the availability of the first Advantage quantum computer physically located in the United States.

That new deployment is part of the USC-Lockheed Martin Quantum Computing Center (QCC) hosted at USC’s Information Sciences Institute (ISI), a unit of the University of Southern California’s prestigious Viterbi School of Engineering. Additionally, Amazon Web Services (AWS) and D-Wave announced that the U.S.-based system is available for use in Amazon 2racket, expanding the number to three different D-Wave quantum systems available to AWS users.

Leap Quantum Cloud Service

 

D-Wave’s customers interface with its systems through the Leap™ quantum cloud service. Leap delivers immediate, real-time access to the company’s Advantage quantum computer and quantum hybrid solver service, all with enterprise-class performance and scalability.

Leap allows developers proficient in Python to get started building and running quantum applications. Through a seamless and secure cloud-based connection, users can easily start solving complex problems of up to 1 million variables and 100,000 constraints.

Using Leap, D-Wave customers have developed quantum hybrid applications for use cases in manufacturing, logistics, financial services, life sciences, materials science, retail and transportation. By eliminating the need to wait hours, days or weeks to get good answers to a broad array of problems, D-Wave is helping businesses move forward.

D-Wave Launch

D-Wave Launch™ is the company’s onboarding platform aimed at helping businesses easily start their quantum journey. Through this program, D-Wave’s team of experts and partners aid enterprises in identifying best use cases for quantum and work with them to develop a proof of concept and production pilot.

From there, the team coordinates with customers to get their hybrid quantum applications up and running, providing ongoing Leap quantum cloud access to ensure the application is operating smoothly and delivering real business value.

Target Verticals

While the potential applications for quantum computing are effectively limitless, D-Wave has identified a number of industry verticals as key areas of focus for its quantum architecture, providing case studies for each. These include:

  • Manufacturing – D-Wave worked with Volkswagen to identify a commercial optimization application, the binary paint shop problem, which was run on D-Wave’s hybrid solver service. The solver outperformed four purely classical methods on problem sizes at commercial scale (N=3,000). In a separate project, similar inputs were tested using a leading ion trap system, which failed to find any commercial solution.
  • Life Sciences – Menten AI makes use of D-Wave quantum computing to assist in the design of novel therapeutic peptides—short strings of amino acids that can act as potent drugs. With the rise of COVID-19, D-Wave’s Advantage system made it possible to identify molecules that might be especially well-suited for binding and inhibiting the related spike protein, producing several promising peptide designs.
  • Finance – Multiverse Computing, a leader in developing quantum solutions for the financial sector, leveraged D-Wave’s hybrid solver service in a collaboration with BBVA, one of the world’s largest financial institutions. Multiverse demonstrated management strategies that far exceeded the granularity of traditional returns in a fraction of the time, helping BBVA identify a low-risk portfolio for investment.

Market Opportunity

The quantum computing total addressable market is projected to grow between $450 billion and $850 billion over the next 15 to 30 years, with between $5 billion and $10 billion of anticipated TAM growth coming in the next three to five years, according to Boston Consulting Group. Driving factors behind this growth include rising investments in quantum computing tech by governments and an increasing number of commercial use-cases.

Forward-thinking organizations see quantum as an opportunity to move ahead of the competition. From finding efficiencies and reducing waste to decreasing time to solution and solving problems abandoned due to complexity, the business value is real. According to data from 451 Research, 40% of large enterprises are already experimenting with quantum computing.

D-Wave is strategically positioned – in an industry with significant barriers to entry – as evident by a decades-long track record serving a roster of blue-chip customers. The company is singularly focused on helping its customers achieve clear value by leveraging quantum computing in practical business applications. With a full stack of systems, software, developer tools and services, D-Wave is working to enable enterprises, governments, developers and researchers to access the power of quantum computing, thereby providing an intriguing opportunity for prospective investors.

D-Wave’s current investor base includes PSP Investments, Goldman Sachs, BDC Capital, NEC Corporation, Aegis Group Partners and In-Q-Tel.

Leadership Team

Dr. Alan Baratz has served as the CEO of D-Wave since 2020. Previously, as Executive Vice President of R&D and Chief Product Officer, he drove the development, delivery, and support of all of D-Wave’s products, technologies, and applications. Dr. Baratz has over 25 years of experience in product development and bringing new products to market at leading technology companies and software startups. As the first president of JavaSoft at Sun Microsystems, he oversaw the growth and adoption of the Java platform from its infancy to a robust platform supporting mission-critical applications in nearly 80 percent of Fortune 1000 companies. He has also held executive positions at Symphony, Avaya, Cisco, and IBM. Dr. Baratz holds a doctorate in computer science from the Massachusetts Institute of Technology.

John Markovich is the company’s CFO. He brings to D-Wave over three decades of experience working with rapidly growing private and public technology companies across all stages of development. Mr. Markovich has directed the finance, accounting, tax, treasury, M&A, legal, operations, customer service, IR, HR, and IT functions for companies ranging from privately held pre-revenue startups to an NYSE-listed Fortune 500 multi-national company with over $1.2 billion in annual revenue. During his career, he has negotiated and closed over 150 debt, equity, M&A, and joint venture transactions exceeding $2.5 billion in value; over a dozen private placements; nearly a dozen M&A transactions; and several international joint ventures. Mr. Markovich holds a BS in Business from Miami University and an MBA from the Michigan State Graduate School of Business.

D-Wave Quantum Inc. (NYSE: QBTS), closed Tuesday's trading session at $1.08, up 6.9307%, on 3,805,620 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.57/$2.7163.

Recent News

Emperor Metals Inc. (CSE: AUOZ) (FRA:9NH) (OTCQB: EMAUF)

The QualityStocks Daily Newsletter would like to spotlight Emperor Metals Inc. (CSE: AUOZ) (FRA:9NH) (OTCQB: EMAUF).

Emperor Metals Inc. (CSE: AUOZ) (FRA:9NH) (OTCQB: EMAUF) is an advanced stage gold exploration company focused on proving and developing the substantial resource potential of its flagship Duquesne West Gold Project located in the Tier 1 district of the Southern Abitibi Greenstone belt of Rouyn-Noranda, Quebec. The Project has a 2011 historical mineral resource estimate of 727,000 ounces of Au at 5.42 g/t and an average thickness of 5.71 m*.

In 2023, with the use of AI (Artificial Intelligence), Emperor Metals created the first ever 3D mineralized and geological model, which illuminated the potential to add significant ounces to this deposit. Using these models, Emperor’s had a very successful 2023 drilling campaign of 8,579 m. In addition to laterally extending high grade zones by intercepting grades of 15.8 g/t Au over 10.8 meters, Emperor encountered intercepts of lower grade bulk tonnage in the host rocks (1.69 g/t Au over 25 m). This led to envisioning a different strategy of exploration and the revelation that a conceptual open-pit potentially overlies this high-grade gold deposit. Historic core sampling began (2,500 m) for discovering overlooked lower grade gold in the host rock around the high-grade lenses. Lower grade bulk tonnage gold improves the open-pit economics by reducing stripping ratios and adding overlooked incremental ounces for open pit mining.

Emperor Metals is set to begin a fully funded Phase II 8,000 m drilling program in May 2024. The company also plans on assaying an additional 8,000 m of historic core within the open pit model. Emperor is working toward producing an updated NI 43-101 Mineral Resource Estimate by Q1 2025.

The company is led by a dynamic group of resource sector professionals who have a strong record of success in evaluating and advancing mining projects from exploration through to production, attracting capital and overcoming adversity to deliver exceptional shareholder value.

Project

Emperor Metals has an option to earn 100% ownership of the Duquesne West Gold Project, a mineral claim package comprising 38 claims covering approximately 1,389 ha (3,432 acres) in Quebec.

The Duquesne West Gold Property is located 32 kilometers northwest of the city of Rouyn-Noranda and 10 kilometers east of the town of Duparquet. The property lies within the historic Duparquet gold mining camp in the southern portion of the Abitibi Greenstone Belt in the Superior Province.

Emperor is targeting the potential multimillion-ounce resource in a combination of conceptual open pit and underground mining scenarios. A Phase I drill campaign and historical core sampling program was completed in 2023, which included resource confirmation and exploration drilling, focusing on delineating and growing the resource toward development.

The property hosts a historical inferred mineral resource estimate of 727,000 ounces of gold at a grade of 5.42 grams per ton (g/t) and average stope thickness of 5.71 m. The mineral resource estimate predates modern Canadian Institute of Mining guidelines, and a Qualified Person on behalf of Emperor Metals has not reviewed or verified the mineral resource estimate. Therefore, it is considered historical in nature and is reported solely to provide an indication of the magnitude of mineralization that could be present on the property. The gold system remains open for resource identification and expansion.

Reinterpretation of the existing geological model was created using artificial intelligence and machine learning. This AI model shows the opportunity for additional discovery of ounces by revealing gold trends unknown to previous workers and the potential to expand the resource along significant gold-endowed structural zones. Multiple scenarios exist to expand additional resources, which include:

  • Underground High-Grade Gold
  • Open Pit Bulk Tonnage Gold
  • Underground Bulk Tonnage Gold

The Duquesne West-Ottoman property straddles the Porcupine-Destor gold localizing fault several kilometers east of the town of Duparquet. A number of previous drill campaigns have outlined an inferred resource of 4.17 million tons grading 5.42 g/t of gold (cut) or 6.36 g/t (uncut), as reported in the NI 43-101 report titled “Technical Report and Mineral Resource Estimate Update for the Duquesne-Ottoman Property, Quebec, Canada.”

Emperor Metals is funded for an 8,000-meter drilling program focusing primarily on adding ounces to the current resource within and lateral to the open pit model. An additional 8,000 m of historical core sampling and assaying is included in the budget to help build incremental ounces in the open-pit environment.

Market Opportunity

The World Gold Council, the industry association for the world’s gold producers, estimated in 2023 the physical financial gold market, which is made up of bars, coins, gold ETFs and central bank reserves, to be worth nearly $5 trillion.

The council reports that gold mine production adds approximately 3,500 tons of the precious metal to the world’s supply annually, equivalent to about 2% growth. This historical scarcity and relatively slow production of new supply, as compared to other commodities, is a primary reason gold has retained its value for millennia, according to the council.

In May 2024, the market price of gold was approximately $2,340 per ounce.

Management Team

John Florek, P.Geol., is President, CEO and Director of Emperor Metals. He has more than 35 years of technical and senior management experience with major and junior mining companies, including roles as founder, vice president and director. He has helped identify and develop significant asset value for mines and exploration projects from grass roots through development. He has worked for several major mineral producers, including BHP, Placer Dome, Barrick, Teck and Detour Gold/Kirkland Lake Gold/Agnico Eagle.

Sean Mager is CFO and Director of Emperor Metals. He has worked more than 30 years in the mining sector, including extensive experience in corporate development, stakeholder relations, regulatory, financial and operations.

Alex Horsley is Head of Corporate Development and Director of Emperor Metals. He has more than 20 years of experience in the mining sector and capital markets with a focus on finance, marketing, management, corporate development and communications. He is founder and former CEO of Emperor Metals. He has assisted in raising more than C$40 million for exploration and development mining companies.

*Power-Fardy and Breede, 2011. The Mineral Resource Estimate (MRE) constructed in 2011 is considered historical in nature as it was constructed prior to the most recent Canadian Institute of Mining and Metallurgy (CIM) standards (2014) and guidelines (2019) for mineral resources. In addition, the economic factors used to demonstrate reasonable prospects of eventual economic extraction for the MRE have changed since 2011. A qualified person has not done sufficient work to consider the MRE as current. Emperor is not treating the historical MRE as current. The reader is cautioned not to treat it, or any part of it, as a current MRE.

Emperor Metals Inc. (OTCQB: EMAUF), closed Tuesday's trading session at $0.0815, even for the day, on 3,000 volume. The average volume for the last 3 months is 91,794 and the stock's 52-week low/high is $0.0597/$0.14505.

Recent News

Nutriband Inc. (NASDAQ: NTRB)

The QualityStocks Daily Newsletter would like to spotlightFathom Nutriband Inc. (NASDAQ: NTRB) .

Nutriband Inc. (NASDAQ: NTRB) is engaged in the development of a portfolio of transdermal pharmaceutical products. The company’s AVERSA™ technology can be incorporated into any transdermal patch and includes aversive agents to prevent abuse, diversion, misuse and accidental exposure to drugs with abuse potential, specifically opioids.

AVERSA technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, such as fentanyl, while making sure that these drugs remain accessible to patients who need them. The technology is covered by a broad intellectual property portfolio with patents granted in the United States, Europe, Japan, Korea, Russia, Canada, Mexico and Australia.

The company’s business model is to apply its transdermal technology to existing FDA-approved drugs with a goal of improving safety, efficacy and patient comfort while qualifying for a limited-development regulatory pathway that reduces the number of clinical trials required for approval of new drugs.

Nutriband has three subsidiaries, including 4P Therapeutics, its clinical and regulatory subsidiary; Pocono Pharmaceutical, a contract manufacturer for a wide range of clients; and Active Intelligence, a developer of sports recovery products. This ownership of manufacturing and clinical development capabilities drastically reduces costs for AVERSA and other technologies.

In April 2024, Nutriband announced that the company had been engaged by and received a first order from Fit For Life Group, a major brand license holder. A fully executed supplier agreement is expected to follow. Nutriband’s wholly owned Active Intelligence subsidiary will act as manufacturer.

The company is headquartered in Orlando, Florida.

Products

Nutriband’s lead product candidate is AVERSA Fentanyl, an abuse-deterrent fentanyl transdermal patch. The company announced in March 2024 that it will submit a New Drug Application to the U.S. Food and Drug Administration seeking approval to market AVERSA Fentanyl.

Nutriband has partnered with Kindeva Drug Delivery, a leading global contract development and manufacturing organization, to incorporate Nutriband’s AVERSA abuse-deterrent transdermal technology into Kindeva’s FDA-approved transdermal fentanyl patch system. Because Nutriband’s abuse-deterrent technology is incorporated into the fentanyl patch but is physically separate from and does not come in contact with the drug layer, the clinical trials typically needed to demonstrate safety and efficacy for a new drug formulation would not be required.

AVERSA Fentanyl has the potential to be the first and only abuse deterrent patch approved anywhere in the world. The company plans to seek an expedited review by the FDA, as has been granted for certain abuse-deterrent oral opioid products, which shortens the regulatory review period to six months from the conventional 10-month FDA review cycle for NDAs.

Nutriband’s AVERSA product development pipeline also includes abuse deterrent versions of currently approved and marketed transdermal patches containing buprenorphine, an opioid used to treat opioid use disorder, and methylphenidate, a central nervous system stimulant used in the treatment of attention deficit hyperactivity disorder (ADHD). Both are labeled with FDA-required warnings for the risk of abuse and misuse, as well as warnings against accidental exposure.

Market Opportunity

Nutriband cites a market analysis report from Boston-based Health Advances, a healthcare and life sciences consulting firm. According to the report, upon FDA approval, AVERSA Fentanyl has the potential to reach peak annual sales of $200 million in the U.S.

The company further states that, should non-abuse-deterrent transdermal fentanyl products lose FDA marketing approval, AVERSA Fentanyl would have greater pricing flexibility and would have the potential to generate more than $500 million in annual revenue.

Management Team

Gareth Sheridan is Co-Founder and CEO of Nutriband. He was Ireland’s ‘Young Entrepreneur of the Year’ in 2014 for establishing Nutriband. He has worked as a Business Mentor with 100 Minds, a social enterprise that brings together some of Ireland’s top college students and connects them with a cause to achieve large charitable goals. He received a B.Sc. in Business and Management from Dublin Institute of Technology.

Serguei Melnik is Co-Founder and President of Nutriband. He has been involved in general business consulting for companies in the U.S. financial markets and setting up legal and financial frameworks for operations of foreign companies in the U.S. He previously was the COO of Florida-based Asconi Corporation. He also was a lawyer in the Department of Foreign Affairs, JSC Bank “Inteprinzbanca,” in Chisinau, Moldova, and prior to that practiced law in Moldova. He is fluent in four languages.

Jeff Patrick, Pharm.D., is Chief Scientific Officer of Nutriband. He currently serves as Director of the Drug Development Institute at the Ohio State University Comprehensive Cancer Center. His prior roles included Global Vice President at Mallinckrodt Pharmaceuticals Inc.; and roles at Dyax, Myogen/Gilead, Actelion and Sanofi-Synthelabo Inc. He was a clinical pharmacist at the University of Tennessee Medical Center and a clinical assistant professor of pharmacy at the University of Tennessee College of Pharmacy.

Gerald Goodman is CFO of Nutriband. He is a certified public accountant with his own firm, Gerald Goodman CPA. He also practiced with Madsen & Associates, CPAs, and was a partner in the accounting firm of Wiener, Goodman & Company. He is also a director of Lifestyle Medical Network Inc., which provides management services to healthcare providers. He is a graduate of Pennsylvania State University, where he received a bachelor’s degree in accounting.

Nutriband Inc. (NASDAQ: NTRB), closed Tuesday's trading session at $7.74, up 3.4759%, on 72,989 volume. The average volume for the last 3 months is 33,924 and the stock's 52-week low/high is $1.53/$9.15.

Recent News

Trillion Energy International Inc. (CSE: TCF) (OTCQB: TRLEF)

The QualityStocks Daily Newsletter would like to spotlight Trillion Energy International Inc. (CSE: TCF) (OTCQB: TRLEF).

Trillion Energy International Inc. (CSE: TCF) (OTCQB: TRLEF), along with its consolidated subsidiaries, is a Canadian oil and gas exploration and production company with operations primarily focused in the Republic of Türkiye.

Headquartered in Canada, the company owns 49% of the SASB natural gas field, which is producing critical domestic supply of natural gas during Europe’s ongoing energy shortages. It also holds a 19.6% (except three wells with 9.8%) ownership interest in the Cendere Oil Field and has a farm-in agreement to earn 50% interest in three oil exploration blocks in southeast Türkiye called Cudi-Gabar.

Trillion Energy utilizes state-of-the-art technology and ingenious practices to produce and distribute oil and natural gas while still maintaining a commitment to sustainable and responsible operations. Whether through the development of new projects or optimizing existing assets, the company continues to seek new and innovative ways to drive growth and value for its stakeholders.

Headquartered in Vancouver, British Columbia, Trillion Energy is led by seasoned professionals who collectively boast over a century of energy exploration and development experience.

Projects

SASB Gas Field

The SASB Gas Field is producing and delivering critical domestic supplies of natural gas as energy shortages grip Europe due to Russia’s invasion of Ukraine.

Located in the southwestern Black Sea, the SASB gas field consists of numerous conventional natural gas pools located in shallow water. The fields have produced over 43 billion cubic feet (BCF) since initial development in 2007 and continue to provide much needed energy to Türkiye and the EU. Total infrastructure to date, including production platforms, pipelines, initial wells and gas processing plant, cost in excess of $600 million.

Trillion Energy is redeveloping the field with a strategic planned program of approximately 17 wells which commenced in 2022. Phase B of the program, targeted for 2024/25, consists of the re-entry of five legacy wells to drill sidetrack development wells and one exploration stratigraphic well.

Cendere Oil Field

Trillion Energy’s Cendere oil field is a long-term, low decline, stable oil production field located in Türkiye. The company has a 19.6% interest in the field, except for three wells in which its interest is 9.8%.

Cash flow after operating costs from the field is $120,000 to $140,000 per month, with average current production netting the company 110-120 barrels of oil per day. Estimated remaining Cendere oil reserves total 1.5 million barrels (0.277 million barrels net Trillion Energy).

The gross value of Trillion Energy’s interest is estimated at $13.85 million (NPV10).

Cudi-Gabar

Trillion Energy’s 10-well oil exploration drilling program is occurring on three prospective oil blocks located in the prolific Cudi-Gabar oil province in southeast Türkiye. The total area of the three blocks is 374,325 acres.

Trillion Energy’s potential 50% working and revenue interest in the blocks is earned by paying 100% of the work program costs. The company will operate the exploration program.
During 2023/24, Trillion Energy will shoot 351 kilometers of 2D seismic (150 km already shot on the eastern block) and drill four wells. The remaining six wells will be paid 50% by Trillion and 50% by the company’s partner. The oil blocks are surrounded by more than 10 major oil discoveries, half of which are recent.

Market Opportunity

A January 2024 report by Emergen Research, a market research and consulting company, estimated the global natural gas market at $310.5 trillion in 2022 and projected the market will be worth $443.8 trillion by 2032, achieving a CAGR of 3.7% during the forecast period. Increasing global economic activity and rising electricity consumption are key factors driving revenue growth of the market, according to the report.

Trillion Energy reports strong demand for natural gas in Türkiye, which is the seventh-largest natural gas consuming country in the world. Türkiye currently imports 98% of the natural gas it consumes, with about 60% of those imports coming from Iran and Russia.

Management Team

Dr. Arthur Halleran is CEO and Director of Trillion Energy. He has a Ph.D. in Geology from the University of Calgary and 44 years of petroleum exploration and development experience. His international experience includes work in Canada, Colombia, Egypt, India, Guinea, Sierra Leone, Sudan, Suriname, Chile, Brazil, Bulgaria, Türkiye, Pakistan, Peru, Tunisia, Trinidad Tobago, Argentina, Ecuador and Guyana. Dr. Halleran has worked for Petro-Canada, Chevron, Rally Energy and United Hydrocarbon International Corp. In 2007, he founded Canacol Energy Ltd., now the largest natural gas producer in Colombia.

Al Thorsen is COO of Trillion Energy. He is responsible for production operations of the SASB gas field, as well as future drilling activities in Türkiye and abroad. Highlights of his career include Valeura Energy Inc. as operations manager in Türkiye; Journey Energy, leading a production team; Rio Alto Exploration as country manager and production manager; Zargon Oil and Gas as VP of Operations; Orleans Energy as VP of Operations; and Central Petroleum as COO. He holds a Bachelor of Science in Petroleum Engineering from Montana College of Mineral Science & Technology.

Trillion Energy International Inc. (OTCQB: TRLEF), closed Tuesday's trading session at $0.10895, up 2.9773%, on 69,255 volume. The average volume for the last 3 months is 147,714 and the stock's 52-week low/high is $0.0682/$1.383.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.